ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Autologous Anti-PRAME TCR-expressing T-cells OPB-201

Its studies are mostly in Endometrial Neoplasms, led by Outpace Bio.

Furthest: phase 1, since Jun 17, 20261 company-led study, 1 open or runningNext primary completion: Jun 2030 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Outpace Bio11 open or runningphase 1since Jun 17, 2026Jun 17, 2026Jun 2030phase 1 · NCT07664735

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 17, 2026First study: phase 1 study in Endometrial NeoplasmsFirst studyNCT07664735 · 30 planned · United States

Ahead

  1. Jun 2030Primary completion: phase 1 study in Endometrial NeoplasmsNCT07664735

TargetBeta

PRAME →read by rule
“A preparation of autologous T-lymphocytes that have been genetically engineered to express a T-cell receptor (TCR) specific for the tumor-associated antigen (TAA) preferentially expressed antigen in melanoma (PRAME), ”NCIt, by rule

Other programs on PRAME

ProgramCompanyFurthest phaseStudies
anzutresgene autoleucelruleimmatics-us-incphase 33
PRAME mRNA Vaccine mRNA-4203ruleimmatics-us-incphase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07664735Endometrial Neoplasms · United States1RecruitingJun 203030

How it is read

Names in the registry

  • “OPB-201”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.